[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


2. de Jong JS, Beukema JC, van Dam GM, Slart R, Lemstra C, Wiggers T: Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol; 2010 Oct;17(10):2656-62
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up.
  • BACKGROUND: Selection of patients with anal cancer for groin irradiation is based on tumor size, palpation, ultrasound, and fine needle cytology.
  • Current staging of anal cancer may result in undertreatment in small tumors and overtreatment of large tumors.
  • This study reports the feasibility of the sentinel lymph node biopsy (SLNB) in patients with anal cancer and whether this improves the selection for inguinal radiotherapy.
  • METHODS: A total of 50 patients with squamous anal cancer were evaluated prospectively.
  • CONCLUSIONS: We conclude that SLNB in anal cancer is technically feasible.
  • However, because of the occurrence of inguinal lymph node metastases after a tumor-negative SLNB, introduction of this procedure as standard of care in all patients with anal carcinoma should be done with caution to avoid undertreatment of patient who otherwise would benefit from inguinal radiotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):238-42 [2672386.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):255-8 [8345551.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):270-4 [9015169.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):156-60 [9084853.001]
  • [Cites] World J Surg. 1997 Oct;21(8):788-92; discussion 793 [9327667.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):31-5 [16372147.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1511-6 [17009151.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Br J Radiol. 2009 Jan;82(973):41-8 [19095815.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Feb;53(1):3-8 [18337684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] ANZ J Surg. 2002 Sep;72(9):651-4 [12269917.001]
  • [Cites] Scand J Surg. 2002;91(4):336-8 [12558082.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1027-9; discussion 1030-1 [12907894.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1032-7 [12907896.001]
  • [Cites] Onkologie. 2003 Oct;26(5):456-60 [14605462.001]
  • [Cites] Cancer Radiother. 2003 Nov;7 Suppl 1:85s-90s [15124549.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):43-8 [6691550.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • (PMID = 20865825.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2941712
  •  go-up   go-down


3. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


Advertisement
4. Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D: Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer; 2005 Apr 11;92(7):1221-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
  • Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer.
  • In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.
  • Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm margin in all directions.
  • Only one patient experienced any grade 3 toxicity (skin).
  • This is a well-tolerated regimen for elderly/poor performance patients with anal cancer, which can achieve high rates of local control and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Frail Elderly

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9 [12118566.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2978-81 [15210736.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • [Cites] Radiology. 1994 May;191(2):569-72 [8153343.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1352-7 [12778060.001]
  • (PMID = 15798772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361984
  •  go-up   go-down


5. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer; 2006 Feb 27;94(4):561-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated quantitative methylation status in oral squamous cell carcinoma patients.
  • Fresh tumour tissue and normal control tissue from resection margin was obtained from 79 consecutive patients undergoing resection of oral squamous cell carcinoma.
  • Cytoglobin is a novel candidate tumour suppressor gene highly methylated in upper aero-digestive tract squamous cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cyclin A / genetics. DNA Methylation. Mouth Neoplasms / genetics. Peroxidases / genetics

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):892-5 [10706101.001]
  • [Cites] Nucleic Acids Res. 1994 Dec 11;22(24):5354-9 [7816625.001]
  • [Cites] FEBS Lett. 2001 Feb 9;490(1-2):75-8 [11172814.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):386-92 [11900224.001]
  • [Cites] Mol Biol Evol. 2002 Apr;19(4):416-21 [11919282.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19538-45 [11893755.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4231-6 [12082610.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4757-66 [12183435.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6395-402 [12214281.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5295-300 [12234999.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3164-71 [12374684.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):109-14 [12406555.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):163-9 [12509970.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3971-5 [12553020.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):41-6 [12672028.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Jun;32(3):233-45 [12767868.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] Adv Exp Med Biol. 2003;532:39-49 [12908548.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2656-9 [7780981.001]
  • [Cites] Ann R Coll Surg Engl. 1996 Jan;78(1 Suppl):14-8 [8659993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):459-70 [9949205.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3518-26 [10416619.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] IUBMB Life. 2004 Nov-Dec;56(11-12):703-7 [15804835.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):1002-6 [15467435.001]
  • [Cites] Mol Carcinog. 2005 Jul;43(3):141-54 [15937959.001]
  • [Cites] Oral Oncol. 2005 Nov;41(10):1034-43 [16129652.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):101-8 [16154320.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2306-9 [14556921.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8902-11 [14654786.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):145-53 [14693237.001]
  • [Cites] Curr Oncol Rep. 2004 Mar;6(2):152-61 [14751093.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1733-42 [15014026.001]
  • [Cites] Hum Genet. 2004 May;114(6):534-40 [15007728.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3825-30 [15173091.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):389-95 [15254736.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5455-63 [15328184.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Anal Biochem. 2004 Oct 1;333(1):119-27 [15351288.001]
  • [Cites] Scand J Dent Res. 1986 Aug;94(4):347-56 [3462898.001]
  • [Cites] Nucleic Acids Res. 1990 Feb 11;18(3):687 [1689825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Oral Oncol. 2000 Sep;36(5):404-13 [10964046.001]
  • (PMID = 16449996.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCNA1 protein, human; 0 / Cadherins; 0 / Cyclin A; 0 / Cyclin A1; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Retinoic Acid; 0 / cytoglobin; 0 / retinoic acid receptor beta; 9004-22-2 / Globins; EC 1.11.1.- / Peroxidases
  • [Other-IDs] NLM/ PMC2361183
  •  go-up   go-down


6. Harris AT, Rennie A, Waqar-Uddin H, Wheatley SR, Ghosh SK, Martin-Hirsch DP, Fisher SE, High AS, Kirkham J, Upile T: Raman spectroscopy in head and neck cancer. Head Neck Oncol; 2010 Oct 05;2:26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early diagnosis of cancer affords early intervention and greatest chance of cure.
  • Raman spectroscopy could confer great patient benefit with early, rapid and accurate diagnosis.
  • It could reduce the need for whole pathological specimen examination, in theatre it could help to determine margin status, and finally peripheral blood diagnosis may be an achievable target.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] Eur J Med Res. 2010 Mar 30;15(3):131-4 [20452899.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63 [11037840.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):448-57 [11952545.001]
  • [Cites] J Biomed Opt. 2003 Jan;8(1):121-47 [12542388.001]
  • [Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]
  • [Cites] Photochem Photobiol. 2003 Aug;78(2):197-204 [12945589.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6679-86 [14640745.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):443-9 [15009728.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):59-68 [15047215.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):860-8 [15513990.001]
  • [Cites] Lasers Surg Med. 2005 Sep;37(3):192-200 [16127671.001]
  • [Cites] Biopolymers. 2006 Feb 15;81(3):179-93 [16231284.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):221-8 [16140566.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3317-22 [16540686.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):021003 [16674178.001]
  • [Cites] Bioinformatics. 2006 Oct 15;22(20):2565-6 [16882648.001]
  • [Cites] Biochem Soc Trans. 2007 Jun;35(Pt 3):544-9 [17511648.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):785-98 [18203445.001]
  • [Cites] Analyst. 2008 Oct;133(10):1416-23 [18810290.001]
  • [Cites] Biopolymers. 2009 Jul;91(7):539-46 [19226625.001]
  • [Cites] Head Neck Oncol. 2009;1:25 [19594907.001]
  • [Cites] Head Neck Oncol. 2009;1:34 [19761601.001]
  • [Cites] Head Neck Oncol. 2009;1:38 [19863815.001]
  • [Cites] Oral Oncol. 2009 Dec;45(12):1006-10 [19828359.001]
  • [Cites] Int J Gynecol Cancer. 2010 Feb;20(2):283-7 [20134271.001]
  • [Cites] Expert Rev Anticancer Ther. 2010 Mar;10(3):321-9 [20214513.001]
  • [Cites] Anal Chem. 2000 Aug 15;72(16):3771-5 [10959962.001]
  • (PMID = 20923567.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2958871
  •  go-up   go-down


7. Chapet O, Gerard JP, Mornex F, Goncalves-Tavan S, Ardiet JM, D'hombres A, Favrel V, Romestaing P: Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience. Int J Colorectal Dis; 2007 Feb;22(2):191-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience.
  • BACKGROUND: To report our patient experience with squamous cell carcinoma of the anal margin and to evaluate the prognostic factors influencing outcome.
  • MATERIALS AND METHODS: Between 1980 and 2001, 26 patients with anal margin squamous cell carcinoma were treated in Lyon-Sud: 7 T1, 14 T2, 4 T3, and 1 T4 with 20 N0, 3 N1, and 3 N2.
  • The anal canal was invaded in five patients.
  • Three factors correlated with specific survival: cell differentiation (P=0.038) and T (P=0.001) and N category (P=0.0005).
  • CONCLUSION: Our results confirm the dominating place of definitive irradiation and radiochemotherapy in the treatment of anal margin squamous cell carcinoma.
  • The prognosis of squamous cell carcinoma is correlated to T and N staging and cell differentiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasms, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] Proc R Soc Med. 1968 Jun;61(6):629-30 [4173822.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1843-8; discussion 1848, 1853-4 [8985968.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):231-4 [371426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):57-66 [9300740.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Radiother Oncol. 1995 Mar;34(3):195-202 [7631025.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):799-808 [2202568.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Surg Gynecol Obstet. 1979 Apr;148(4):576-8 [432774.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Acta Oncol. 2001;40(1):29-33 [11321656.001]
  • [Cites] Radiother Oncol. 1988 Jan;11(1):1-6 [3344351.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 16799791.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • Tumors of the anal canal and anal margin are rare.
  • Cancers are infrequent and consisted of well-differentiated squamous cell carcinoma, or poorly differentiated basaloid squamous cell carcinoma.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


9. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • A surgical excision (close or positive surgical margin in 22 out of 29 patients) was realized before radiotherapy (RT).
  • The overall anal conservation rate was 80% for the whole series.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • RESULTS: Overall survival and colostomy-free survival rates for patients with anal canal cancer were 75 percent and 87 percent at five years, respectively.
  • Patients with anal margin cancer had a less favorable outcome with five-year-overall and colostomy-free survival rates of 54 percent and 69 percent, respectively.
  • After correction for imbalance between anal canal and anal margin tumors, i.e., exclusion of T1 tumors of the anal canal, difference in overall survival remained significant (73 percent vs. 54 percent, P = 0.01).
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Kreuter A, Brockmeyer NH, Wieland U: [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients]. Hautarzt; 2010 Jan;61(1):21-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients].
  • Anal dysplasia is common in HIV patients, especially in HIV-positive men having sex with men (MSM).
  • High-grade anal dysplasia can progress to invasive anal cancer.
  • As in cervical carcinoma, there is a cause and effect relationship between anal cancer and human papillomavirus (HPV) infection, especially with high-risk types such as HPV16.
  • Several experts have recommended screening programs for anal cancer, including anal cytology along the lines of the Pap smear in women.
  • Clinical inspection, lesion biopsy, and treatment of anal dysplasia are performed under high-resolution anoscopy.
  • Anal cancer is divided into cancer of the anal margin and cancer of the anal canal.
  • Early cancer of the anal margin is excised akin to squamous cell cancer of the exposed skin, whereas cancer of the anal canal is treated by radiochemotherapy.
  • However, side effects, especially acute post-irradiation skin toxicity, early local recurrences, and abdominoperineal rectal excision are more common in HIV-positive patients.
  • Physicians working in the field of HIV/AIDS should regularly screen their patients for the presence of anal dysplasia and anal cancer.
  • Basic diagnostic workup includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Carcinoma in Situ / virology. HIV Infections / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34 [18410393.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):433-8 [19587592.001]
  • (PMID = 19967333.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Devaraj B, Cosman BC: Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum; 2006 Jan;49(1):36-40
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expectant management of anal squamous dysplasia in patients with HIV.
  • PURPOSE: Anal squamous dysplasia is commonly found in patients with HIV infection.
  • This study reviews a series of patients with HIV and an abnormal anal examination who had squamous dysplasia and who have been followed with physical examination alone and with repeat biopsies as necessary for new or suspicious lesions.
  • METHODS: We reviewed the charts of 40 HIV-positive men who had squamous dysplasia of the anal canal and anal margin, focusing on history, physical findings, histologic diagnosis, and the occurrence of invasive squamous-cell carcinoma.
  • RESULTS: Forty HIV-positive men (mean age, 39 years) were followed for anal squamous dysplasia.
  • Three patients developed invasive carcinoma while under surveillance, and these were completely excised or cured with chemoradiation.
  • Physical examination surveillance for invasive carcinoma may be acceptable for following patients with HIV and biopsy-proven squamous dysplasia.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colectomy / methods. Decision Making. HIV / immunology. HIV Antibodies / immunology. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50 [16972138.001]
  • (PMID = 16283561.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Antibodies
  •  go-up   go-down


13. Heitland W: [Diagnosis and therapy for anal carcinoma]. Chirurg; 2008 Feb;79(2):183-91; quiz 192
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy for anal carcinoma].
  • Of all carcinomas in the anal canal, 75-80% are squamous cell carcinomas-the remaining 25% being adenocarcinomas.
  • Carcinomas of the anal margin are to be differentiated from basal cell carcinomas and Paget's and Bowen's diseases.
  • More than 80% of anal carcinomas show high-risk HP viruses.
  • Every suspicious lesion in the anal canal and margins must be examined histologically.
  • Primary radiochemotherapy is the first treatment option for epidermoid carcinomas of the anal canal and anal margin.
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):411-5 [6329504.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):16-22 [15690652.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 18227955.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • Sensitivity of two consecutive elevated SCC levels during the follow up period in patients who achieved a CR to predict for relapse was 0.56 and specificity 0.83.
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Dwyer MK, Gebski VJ, Jayamohan J: The bottom line: outcomes after conservation treatment in anal cancer. Australas Radiol; 2006 Feb;50(1):46-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bottom line: outcomes after conservation treatment in anal cancer.
  • At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
  • Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499727.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS: Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol; 2010 Jun;162(6):1269-77
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.
  • OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.
  • METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
  • Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.
  • Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.
  • Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.
  • All anal cancers carried high-risk α-HPV types.
  • All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.
  • In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).
  • In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.
  • Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.
  • CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.
  • Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20184584.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Allal AS, Bründler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis; 2005 Mar;20(2):161-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
  • BACKGROUND: Histologically, tumors of the anal region are either keratinizing (K) or non-keratinizing (NK) squamous cell carcinomas (SCCA).
  • METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with anal canal cancers.
  • RESULTS: There were 64 NK and 34 K SCC.
  • The more distal the tumor is (anal margin), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma, Squamous Cell / metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):210-4 [9683295.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):223-30 [11451553.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):214-9 [12562647.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 15688099.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


19. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • METHODS: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • Treatment of primary SCC was chemotherapy +/- radiotherapy alone (n = 29), chemotherapy +/- radiotherapy + surgery (n = 15), or surgery alone (n = 8).
  • Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33).
  • Risk factors associated with worse overall survival included synchronous disease (HR = 4.09), hepatic metastasis > 5 cm (HR = 1.71) and positive surgical resection margin (HR = 1.83).
  • CONCLUSIONS: The majority of patients will recur following hepatic resection of SCC.
  • Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery


20. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


21. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • To obtain a clear surgical margin, APR frequently includes a significant perineal exenteration, leaving a large defect surrounded by irradiated tissue.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • A positive resection margin was the strongest negative predictor of survival after salvage surgery (P = 0.008, log rank test).
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Colecchia M, Nicolai N, Secchi P, Bandieramonte G, Paganoni AM, Sangalli LM, Pizzocaro G, Piva L, Salvioni R: pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. Anal Quant Cytol Histol; 2009 Jun;31(3):153-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy.
  • OBJECTIVE: To evaluate the pathologic characteristics that are associated with outcomes in pT1 penile squamous cell carcinoma (SCC) treated with laser excision.
  • Specimens were reviewed to reassess stage, grade, invasion depth, carcinoma in situ, margins, tumor extension, lymphovascular invasion and human papillomavirus infection.
  • CONCLUSION: Histopathologic parameters such as margin status, depth of invasion and tumor extension are predictors of LR in T1 penile SCC treated by CO2 laser excision.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639702.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • She represented in 2005 with a new lesion distinct from the margin of her first disease occurrence.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Lewin MR, Fenton H, Burkart AL, Sheridan T, Abu-Alfa AK, Montgomery EA: Poorly differentiated colorectal carcinoma with invasion restricted to lamina propria (intramucosal carcinoma): a follow-up study of 15 cases. Am J Surg Pathol; 2007 Dec;31(12):1882-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated colorectal carcinoma with invasion restricted to lamina propria (intramucosal carcinoma): a follow-up study of 15 cases.
  • Invasive colorectal carcinomas (CRCs) with invasion confined to the lamina propria (LP) [intramucosal carcinoma (IMC)] lack access to lymphatics and therefore have no potential for metastases and local intervention (usually polypectomy) should be adequate treatment.
  • It is believed that carcinomas invading the submucosa with unfavorable histology (tumors at/near the margin, and/or vascular invasion, and/or poor differentiation) require additional intervention after polypectomy, whereas those with favorable histology can be safely treated endoscopically.
  • Three cases had signet ring cell differentiation, 1 had focal small cell features, and another had focal squamous differentiation.
  • The remaining 7 patients were treated with partial colectomy (6) or low anterior resection (1), and of these, 5 had no infiltrating carcinoma and negative lymph nodes.
  • One patient had a separate large colorectal (T3) carcinoma with 8/10 positive regional lymph nodes; the IMC seen on biopsy was presumably a metastasis as it was unassociated with an in situ component.
  • Finally, the resected rectum from which an IMC had been previously detected had no residual invasive carcinoma, but the anal skin was involved by Paget disease.
  • Thus, of the 15 cases of PD CRCs limited to the LP, 1 was a metastasis from a separate CRC and another had associated Paget disease of the anal skin.
  • [MeSH-major] Carcinoma in Situ / pathology. Colorectal Neoplasms / pathology. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Oct;32(10):1586-8; author reply 1588-9 [18724239.001]
  • (PMID = 18043043.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement